moxifloxacin has been researched along with Cystic Fibrosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A | 1 |
| Darley, DR; Glanville, AR; Goeman, EE; Jensen, TO; Marriott, DJ; Shaw, K | 1 |
| Catavitello, C; Confalone, P; D'Antonio, D; Di Bonaventura, G; Fiscarelli, E; Picciani, C; Piccolomini, R; Pompilio, A; Savini, V | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Blau, H; Fabian, I; Halperin, D; Klein, K; Shalit, I | 1 |
| Botzenhart, K; Dalhoff, A; Döring, G; Kaygin, H; Steinhuber, A; Worlitzsch, D | 1 |
6 other study(ies) available for moxifloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine | 2009 |
Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.
Topics: Adult; Allografts; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Immunosuppression Therapy; Isoniazid; Latent Tuberculosis; Lung Transplantation; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pseudomonas aeruginosa; Rifampin; Tissue Donors; Tuberculosis, Pulmonary | 2016 |
Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Stenotrophomonas maltophilia | 2010 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Bronchi; Cell Line; Ciprofloxacin; Cystic Fibrosis; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Moxifloxacin; NF-kappa B; Phosphorylation; Quinolines; Tumor Necrosis Factor-alpha | 2007 |
Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Blotting, Northern; Blotting, Western; Coloring Agents; Congo Red; Cystic Fibrosis; Fluoroquinolones; Gentamicins; Granuloma; Hemolysis; HLA Antigens; Humans; Leukocyte Elastase; Male; Moxifloxacin; Penicillins; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcal Protein A; Staphylococcus aureus | 2001 |